text-align:justify;">Therapeutic indications.
AGOVIRAX is indicated for the prevention and supportive treatment of respiratory viral infections.
AGOVIRAX may shorten the duration of flu-like illness and reduce the severity of cold symptoms. AGOVIRAX may reduce the risk of new infections and recurrence of viral cold symptoms.
AGOVIRAX can be used as an adjunct to the prophylactic and persistent hydration of the nasal mucosa, as well as for the prevention and supportive treatment of all complaints caused by dry and irritated nasal mucosa.

What are the properties of AGOVIRAX?
Low humidity and air pollution can cause dry nasal mucosa. However, the nose is only able to perform its filtering function if the nasal mucosa is sufficiently moisturized. AGOVIRAX forms a moisturizing protective layer on the nasal mucosa. This liquid layer serves as a barrier against external influences. Persistent hydration can protect against common cold and flu-like illnesses caused by the cold virus.
The nose is the most common route of infection for viruses that cause colds and flu-like illnesses. Influenza-like illnesses are caused by viruses such as rhinoviruses and coronaviruses. Once in the nose, the viruses can attach to the mucous membranes and infect the mucous cells in which they multiply and spread. It causes typical cold symptoms such as a stuffy nose or runny nose, sore throat and / or headache, cough, and so on.
Often in the early stages of the disease, you cannot tell the difference between a cold and the flu. Influenza is a potentially serious disease; a doctor is needed for the final diagnosis.
AGOVIRAX contains Carragelose®, a marine substance derived from red algae. Carragelose® has two positive effects.

AGOVIRAX forms a protective barrier against cold viruses. Colds and flu-like illnesses are caused by many different viruses, such as rhinoviruses and coronaviruses. Carragelose® (iota-carrageenan) non-specifically packs cold viruses and prevents them from attaching to the mucous membranes. This reduces the reproduction and spread of the viruses responsible for respiratory infections. As with influenza-like viruses, the non-specific coating activity of Carragelose® (iota-carrageenan) in cell culture assays (in vitro) has been demonstrated for SARS-CoV-2. Even if AGOVIRAX cannot completely prevent SARS-CoV-2 infection, it may significantly reduce the risk of infection and spread of the virus.
AGOVIRAX forms a moisturizing protective film. Due to the action of Carragelose® (iota-carrageenan), this film stays on the nasal mucosa longer and acts as a physical barrier against external influences. This physiological moisture film supports the body's natural defenses against cold viruses.

HALSA PHARMA GMBH